ES2842225T3 - Cristales de derivado de diazabiciclooctano y método de producción para cristales de derivado de diazabiciclooctano - Google Patents

Cristales de derivado de diazabiciclooctano y método de producción para cristales de derivado de diazabiciclooctano Download PDF

Info

Publication number
ES2842225T3
ES2842225T3 ES14852849T ES14852849T ES2842225T3 ES 2842225 T3 ES2842225 T3 ES 2842225T3 ES 14852849 T ES14852849 T ES 14852849T ES 14852849 T ES14852849 T ES 14852849T ES 2842225 T3 ES2842225 T3 ES 2842225T3
Authority
ES
Spain
Prior art keywords
tert
compound
formula
amino
oxo
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES14852849T
Other languages
English (en)
Spanish (es)
Inventor
Takao Abe
Takeshi Furuuchi
Yoshiaki Sakamaki
Nakako Mitsuhashi
Yumiko Saito
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Meiji Seika Pharma Co Ltd
Original Assignee
Meiji Seika Pharma Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Meiji Seika Pharma Co Ltd filed Critical Meiji Seika Pharma Co Ltd
Application granted granted Critical
Publication of ES2842225T3 publication Critical patent/ES2842225T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/08Bridged systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425Thiazoles
    • A61K31/429Thiazoles condensed with heterocyclic ring systems
    • A61K31/43Compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula, e.g. penicillins, penems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/439Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/542Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/545Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07BGENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13Crystalline forms, e.g. polymorphs
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02PCLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00Technologies relating to chemical industry
    • Y02P20/50Improvements relating to the production of bulk chemicals
    • Y02P20/55Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
ES14852849T 2013-10-08 2014-10-08 Cristales de derivado de diazabiciclooctano y método de producción para cristales de derivado de diazabiciclooctano Active ES2842225T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2013211242 2013-10-08
PCT/JP2014/076875 WO2015053297A1 (ja) 2013-10-08 2014-10-08 ジアザビシクロオクタン誘導体の結晶とその製造法

Publications (1)

Publication Number Publication Date
ES2842225T3 true ES2842225T3 (es) 2021-07-13

Family

ID=52813113

Family Applications (2)

Application Number Title Priority Date Filing Date
ES14852849T Active ES2842225T3 (es) 2013-10-08 2014-10-08 Cristales de derivado de diazabiciclooctano y método de producción para cristales de derivado de diazabiciclooctano
ES17195437T Active ES2901198T3 (es) 2013-10-08 2014-10-08 Formas cristalinas de derivado de diazabiciclooctano y procedimiento de producción de las mismas

Family Applications After (1)

Application Number Title Priority Date Filing Date
ES17195437T Active ES2901198T3 (es) 2013-10-08 2014-10-08 Formas cristalinas de derivado de diazabiciclooctano y procedimiento de producción de las mismas

Country Status (22)

Country Link
US (5) US10131665B2 (enExample)
EP (4) EP3067355B1 (enExample)
JP (3) JP6617029B2 (enExample)
KR (2) KR102487297B1 (enExample)
CN (2) CN105612159A (enExample)
AR (4) AR097971A1 (enExample)
AU (1) AU2014332960B2 (enExample)
BR (2) BR122022016622B1 (enExample)
CA (2) CA2926071C (enExample)
DK (1) DK3067355T3 (enExample)
ES (2) ES2842225T3 (enExample)
HK (1) HK1219479A1 (enExample)
HU (1) HUE051925T2 (enExample)
IL (2) IL244969B (enExample)
MX (2) MX361659B (enExample)
MY (1) MY199066A (enExample)
NZ (5) NZ757220A (enExample)
RU (1) RU2695219C2 (enExample)
SG (1) SG11201602723RA (enExample)
TW (1) TWI673269B (enExample)
WO (1) WO2015053297A1 (enExample)
ZA (1) ZA201602054B (enExample)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG10201605368UA (en) 2012-05-30 2016-08-30 Meiji Seika Pharma Co Ltd NOVEL β-LACTAMASE INHIBITOR AND PROCESS FOR PREPARING THE SAME
AU2014324302B2 (en) 2013-09-24 2018-02-15 Meiji Seika Pharma Co., Ltd. Production method for diazabicyclooctane derivative and intermediary body thereof
CN105612159A (zh) 2013-10-08 2016-05-25 明治制果药业株式会社 二氮杂二环辛烷衍生物的结晶及其制备方法
CA2969192C (en) * 2014-12-05 2023-02-28 Meiji Seika Pharma Co., Ltd. A process for producing crystals of a diazabicylooctane derivative and a stable lyophilized composition thereof
US10208041B2 (en) * 2016-10-07 2019-02-19 Hoffman-La Roche Inc. Diazabicyclooctane compounds
US11299467B2 (en) 2017-07-21 2022-04-12 Antabio Sas Chemical compounds
US10584123B2 (en) 2017-09-27 2020-03-10 Fedora Pharmaceuticals Inc. Pharmaceutical forms of diazabicyclooctane derivatives and manufacturing method thereof
US10682413B2 (en) 2017-09-27 2020-06-16 Fedora Pharmaceuticals Inc. Pharmaceutical forms of diazabicyclooctane derivatives and process for producing the same
EP3687992A1 (en) 2017-09-27 2020-08-05 Meiji Seika Pharma Co., Ltd. Crystalline forms of diazabicyclooctane derivatives and production process thereof
CN107991404B (zh) * 2017-11-23 2021-01-08 中山奕安泰医药科技有限公司 一种(2s,5r)-苄氧胺基哌啶-2-甲酰胺的检测方法
CN107941944B (zh) * 2017-11-23 2020-09-15 中山奕安泰医药科技有限公司 一种(2s,5r)-苄氧胺基哌啶-2-甲酸乙酯草酸盐的检测方法
EP3572411A1 (en) 2018-05-21 2019-11-27 Antabio SAS Thiazole derivatives as metallo-beta-lactamase inhibitors
JP7523354B2 (ja) * 2018-09-21 2024-07-26 株式会社エーピーアイ コーポレーション アミノ酸誘導体の製造方法
CN115315297B (zh) * 2020-07-13 2024-06-04 日本碍子株式会社 精制方法
CN113552250A (zh) * 2021-06-30 2021-10-26 海南海灵化学制药有限公司 一种盐酸头孢唑兰的杂质检测方法
WO2024263708A2 (en) * 2023-06-23 2024-12-26 Board Of Trustees Of Michigan State University Ornithine decarboxylase (odc) inhibitors and uses thereof

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5038509B1 (enExample) 1970-10-21 1975-12-10
GB1589317A (en) 1977-11-24 1981-05-13 Lilly Co Eli Freeze drying cephalothin sodium
JPS6019759B2 (ja) 1977-11-24 1985-05-17 イ−ライ・リリ−・アンド・カンパニ− 非経口投予用11115152139199東京都中央区京橋2丁目3番13号
JPS60255723A (ja) 1984-05-31 1985-12-17 Ono Pharmaceut Co Ltd メシル酸ガベキサートの結晶性凍結乾燥製剤及びその製造方法
JPH07117533B2 (ja) 1985-08-28 1995-12-18 株式会社生体科学研究所 トランスフエリンおよびその用途
US20030220521A1 (en) 1989-07-27 2003-11-27 G.D. Searle & Co. Renal-selective prodrugs for control of renal sympathetic nerve activity in the treatment of hypertension
TW264475B (enExample) 1991-09-20 1995-12-01 Takeda Pharm Industry Co Ltd
JP2843444B2 (ja) 1994-05-02 1999-01-06 塩野義製薬株式会社 ピロリジルチオカルバペネム誘導体の結晶,該結晶を含む凍結乾燥製剤,およびその製造方法
US6111098A (en) 1994-05-02 2000-08-29 Shionogi & Co., Ltd. Crystal of pyrrolidylthiocarbapenem derivative, lyophilized preparation containing said crystal, and process for producing the same
DE19531874C1 (de) 1995-08-30 1996-10-02 Daimler Benz Ag Seitenwandbaugruppe für eine Kraftfahrzeugkarosserie
FR2812635B1 (fr) * 2000-08-01 2002-10-11 Aventis Pharma Sa Nouveaux composes heterocycliques, preparation et utilisation comme medicaments notamment comme anti- bacteriens
FR2825705B1 (fr) 2001-06-08 2005-05-20 Aventis Pharma Sa Nouveaux composes heterocycliques, leur preparation et leur utilisation comme medicaments, notamment comme anti-bacteriens
FR2835186B1 (fr) 2002-01-28 2006-10-20 Aventis Pharma Sa Nouveaux composes heterocycliques, actifs comme inhibiteurs de beta-lactamases
FR2921060B1 (fr) 2007-09-14 2012-06-15 Novexel Nouveau procede de preparation d'une piperidine disubsituee et nouveaux intermediaires
EP2231667B1 (en) * 2008-01-18 2013-09-04 Merck Sharp & Dohme Corp. Beta-lactamase inhibitors
FR2930553B1 (fr) 2008-04-29 2010-05-21 Novexel Composes azabicycliques, leur preparation et leur utilisation comme medicaments, notamment inhibiteurs de beta-lactamases
FR2936798B1 (fr) 2008-10-03 2012-09-28 Novexel Nouveaux composes heterocycliques azotes, leur preparation et leur utilisation comme medicaments antibacteriens.
US20120053350A1 (en) 2009-04-30 2012-03-01 Ian Mangion Preparation of alkyl esters of n-protected oxo-azacycloalkylcarboxylic acids
FR2951171A1 (fr) 2009-10-09 2011-04-15 Novexel Nouveau sel de sodium d'un compose azabicyclique sous forme enantiomere cristallisee et nouvelles formes polymorphes et pseudopolymorphes ainsi que leur preparation
JP2012122603A (ja) 2010-11-15 2012-06-28 Nifco Inc コネクタ装置
US8772490B2 (en) 2010-12-22 2014-07-08 Meiji Seika Pharma Co., Ltd. Optically active diazabicyclooctane derivatives and process for preparing the same
SG191320A1 (en) 2010-12-22 2013-07-31 Meiji Seika Pharma Co Ltd Optically-active diazabicyclooctane derivative and method for manufacturing same
ES2560404T3 (es) * 2011-06-17 2016-02-18 Astrazeneca Ab Procesos para preparar compuestos heterocíclicos, incluida trans-7-oxo-6-(sulfooxi)-1,6-diazabiciclo[3,2,1]octano-2-carboxamida y sales de la misma
RU2636147C1 (ru) 2011-08-27 2017-11-21 Вокхардт Лимитед Производные 1,6-диазабицикло[3,2,1]октан-7-она и их применение при лечении бактериальных инфекционных болезней
BR112013032974A2 (pt) 2011-08-30 2016-09-06 Wockhardt Ltd "derivados de 1,6-diazabiciclo [3,2,1]-octan-7-ona, seus usos, e composições farmacêuticas".
MX349827B (es) 2011-09-13 2017-08-14 Wockhardt Ltd Compuestos que contienen nitrogeno y su uso.
US8796257B2 (en) * 2011-12-02 2014-08-05 Naeja Pharmaceutical Inc. Bicyclic compounds and their use as antibacterial agents and β-lactamase inhibitors
US9505761B2 (en) 2011-12-02 2016-11-29 Fedora Pharmaceuticals Inc. Bicyclic compounds and their use as antibacterial agents and beta-lactamase inhibitors
SG10201605368UA (en) 2012-05-30 2016-08-30 Meiji Seika Pharma Co Ltd NOVEL β-LACTAMASE INHIBITOR AND PROCESS FOR PREPARING THE SAME
EP2961751B1 (en) * 2012-08-25 2018-03-21 Wockhardt Limited 1,6- diazabicyclo [3,2,1]octan- 7- one derivatives and their use in the treatment of bacterial infections
AU2014324302B2 (en) 2013-09-24 2018-02-15 Meiji Seika Pharma Co., Ltd. Production method for diazabicyclooctane derivative and intermediary body thereof
CN105612159A (zh) 2013-10-08 2016-05-25 明治制果药业株式会社 二氮杂二环辛烷衍生物的结晶及其制备方法
BR112016022437A2 (pt) 2014-03-29 2017-08-15 Wockhardt Ltd Processo para preparação de (2s,5r)-6-(benziloxi)-7-oxo-1,6- diazabiciclo[3,2,1]octano-2-carboxilato de sódio
CA2969192C (en) 2014-12-05 2023-02-28 Meiji Seika Pharma Co., Ltd. A process for producing crystals of a diazabicylooctane derivative and a stable lyophilized composition thereof

Also Published As

Publication number Publication date
JP2020007366A (ja) 2020-01-16
NZ757221A (en) 2021-12-24
NZ743374A (en) 2021-12-24
CN105612159A (zh) 2016-05-25
US20220348578A1 (en) 2022-11-03
US11414417B2 (en) 2022-08-16
JPWO2015053297A1 (ja) 2017-03-09
MY199066A (en) 2023-10-12
IL289275B (en) 2022-10-01
KR102487297B1 (ko) 2023-01-12
HK1250030A1 (en) 2018-11-23
KR20160065871A (ko) 2016-06-09
RU2019115119A (ru) 2019-05-29
CA3110803C (en) 2022-09-27
RU2695219C2 (ru) 2019-07-22
EP3067355A4 (en) 2017-04-26
WO2015053297A1 (ja) 2015-04-16
IL289275A (en) 2022-02-01
EP3067355B1 (en) 2020-12-16
TWI673269B (zh) 2019-10-01
CA2926071C (en) 2021-11-09
DK3067355T3 (da) 2021-01-04
US20200181143A1 (en) 2020-06-11
EP3299370A1 (en) 2018-03-28
RU2016116501A (ru) 2017-11-15
US10131665B2 (en) 2018-11-20
US20190031659A1 (en) 2019-01-31
JP6995810B2 (ja) 2022-01-17
IL289275B2 (en) 2023-02-01
JP6617029B2 (ja) 2019-12-04
IL244969B (en) 2022-01-01
US20160272641A1 (en) 2016-09-22
HK1219479A1 (zh) 2017-04-07
EP3613741A1 (en) 2020-02-26
BR112016006266A2 (enExample) 2017-08-22
RU2019115119A3 (enExample) 2022-04-26
BR112016006266B1 (pt) 2022-11-16
EP3299370B1 (en) 2021-11-24
SG11201602723RA (en) 2016-05-30
BR122022016622B1 (pt) 2023-11-07
KR102388529B1 (ko) 2022-04-20
AR132029A2 (es) 2025-05-21
MX383661B (es) 2025-03-14
NZ757220A (en) 2021-12-24
MX361659B (es) 2018-12-13
NZ757222A (en) 2021-12-24
AU2014332960A1 (en) 2016-05-26
ZA201602054B (en) 2019-06-26
NZ719568A (en) 2018-06-29
JP2021193107A (ja) 2021-12-23
AR097971A1 (es) 2016-04-20
TW201605855A (zh) 2016-02-16
JP7182677B2 (ja) 2022-12-02
AU2014332960B2 (en) 2018-03-29
HUE051925T2 (hu) 2021-04-28
AR132028A2 (es) 2025-05-21
ES2901198T3 (es) 2022-03-21
KR20220054694A (ko) 2022-05-03
CA3110803A1 (en) 2015-04-16
CA2926071A1 (en) 2015-04-16
MX2016004506A (es) 2016-06-16
EP3613740A1 (en) 2020-02-26
US10604522B2 (en) 2020-03-31
US20250059191A1 (en) 2025-02-20
EP3067355A1 (en) 2016-09-14
AR132030A2 (es) 2025-05-21
US12221443B2 (en) 2025-02-11
CN111153903A (zh) 2020-05-15
RU2016116501A3 (enExample) 2018-07-12
IL244969A0 (en) 2016-05-31

Similar Documents

Publication Publication Date Title
ES2842225T3 (es) Cristales de derivado de diazabiciclooctano y método de producción para cristales de derivado de diazabiciclooctano
RU2847390C2 (ru) Кристаллические формы производного диазабициклооктана и способ их получения
RU2840014C2 (ru) Кристаллические формы производного диазабициклооктана и способ их получения
RU2838718C2 (ru) Кристаллические формы производного диазабициклооктана и способ их получения
RU2801220C2 (ru) Кристаллические формы производного диазабициклооктана и способ их получения
HK40023145A (en) Preparation of a diazabicyclooctane derivative
HK40023146A (en) Preparation of a diazabicyclooctane derivative
HK1226731A1 (en) Crystals of diazabicyclooctane derivative and production method for crystals of diazabicyclooctane derivative
HK1226731B (en) Crystals of diazabicyclooctane derivative and production method for crystals of diazabicyclooctane derivative
HK40027891A (zh) 二氮杂二环辛烷衍生物的结晶及其制备方法和应用以及医药组合物
HK1250030B (en) Crystalline forms of diazabicyclooctane derivative and production process thereof